A Class of Central Analgesics

Total Page:16

File Type:pdf, Size:1020Kb

A Class of Central Analgesics Proc. Natl. Acad. Sci. USA Vol. 95, pp. 12028–12033, September 1998 Pharmacology Aminophosphinic inhibitors as transition state analogues of enkephalin-degrading enzymes: A class of central analgesics HUIXIONG CHEN,FLORENCE NOBLE,PASCALE CORIC,MARIE-CLAUDE FOURNIE-ZALUSKI, AND BERNARD P. ROQUES* De´partementde Pharmacochimie Mole´culaireet Structurale, U 266 Institut National de la Sante´et de la Recherche Me´dicale–Unite´de Recherche Associe´e D1500 Centre National de la Recherche Scientifique, Unite´de Formation et de Recherche des Sciences Pharmaceutiques et Biologiques, 4, avenue de l’Observatoire, 75270 Paris Cedex 06, France Communicated by Jean-Pierre Changeux, Institut Pasteur, Paris Cedex 15, France, July 20, 1998 (received for review March 31, 1998) ABSTRACT Inhibition of aminopeptidase N and neutral thiorphan, a selective NEP inhibitor, or bestatin, an APN endopeptidase-24.11, two zinc metallopeptidases involved in inhibitor, did not significantly prevent [3H]Met-enkephalin the inactivation of the opioid peptides enkephalins, produces catabolism whereas their combination resulted in a clear potent physiological analgesic responses, without major side- reduction of the peptide degradation. This result has been effects, in all animal models of pain in which morphine is confirmed in vivo. Thus, because of the complementary role of active. Dual inhibitors of both enzymes could fill the gap NEP and APN in enkephalin inactivation, selective inhibition between opioid analgesics and antalgics. Until now, attempts of only one of these peptidases gives weak antinociceptive to find a compound with high affinity both for neutral responses whereas strong analgesic effects can be obtained endopeptidase and aminopeptidase N have failed. We report after complete inhibition of opioid peptide metabolism with here the design of dual competitive inhibitors of both enzymes combination of selective inhibitors (5). This leads us to pro- with KI values in the nanomolar range. These have been pose the concept of ‘‘dual’’ inhibitors. Accordingly, com- 9 9 obtained by selecting R1,R2, and R3 determinants in amin- pounds able to interact with the S1 and S2 subsites of NEP and ophosphinic-containing inhibitors: NH2OCH(R1)P(O)O APN, such as kelatorphan (5, 6) and RB 38A (7), were shown (OH)CH2OCH(R2)CONHOCH(R3)COOH, for optimal rec- to produce strong analgesic responses caused by a large ognition of the two enkephalin inactivating enzymes, whose increase in the extracellular levels of enkephalins (4). How- active site peculiarities, determined by site-directed mutagen- ever, these compounds (Fig. 1), which contain a hydroxamate esis, have been taken into account. The best inhibitors were as zinc chelating group, were unable to cross the blood–brain 103 more potent than described dual inhibitors in alleviating barrier, and their affinities for APN were '1003 lower than ' 29 acute and inflammatory nociceptive stimuli in mice, thus those for NEP (KI 10 M). These problems were recently providing a basis for the development of a family of analgesics overcome by designing ‘‘mixed inhibitor prodrugs’’ made of devoid of opioid side effects. potent and selective thiol-containing inhibitors of APN and NEP linked by a disulfide bond (8), which was shown to be Acute and chronic pain are incapacitating diseases, and an cleaved in brain (9), where the targeted enzymes are localized improvement in their management is a high priority. Two (2). One of these compounds, RB 101, has been studied classes of pain-alleviating substances currently are used in extensively. After i.p. administration, it has been shown by clinic. The first one is constituted by morphine and surrogates, microdialysis in the nucleus accumbens of freely moving rats which are the most potent and useful compounds to reduce that RB 101 induced a long lasting increase in the extracellular severe pain, including pain associated with terminal issues. level of Met-enkephalin-like material (10). Moreover, RB 101 Antalgics including aspirin, paracetamol, and related sub- has proved to be very potent after systemic administration in stances provide the second group. These compounds inhibit all animal models of pain without producing the side effects of the formation of hyperalgesic substances such as prostaglan- morphine (11). RB 101 is now in preclinical studies. Given dins and are efficient in reducing inflammatory pain. However, these promising results, it was of major interest to develop a there is a need for compounds capable of filling the gap single molecule capable of inhibiting both NEP and APN with between opioids and antalgics, which could be used for the nanomolar affinities as achieved for dual inhibitors of the two treatment of postoperative, osteoarticular, and neuropathic endopeptidases NEP and angiotensin-converting enzyme (12). pain as well as pain in children and in the elderly. Previous attempts with hydroxamate or thiol inhibitors were One of the most promising avenues in the search for such unsuccessful mainly because these compounds did not fit compounds is to improve the potency of the physiological perfectly the active site of each enzyme. system of pain control (1), constituted by the endogenous It recently has been confirmed, by site directed mutagenesis opioid peptides, enkephalins which interact with two specific experiments, that the positively charged amino group in APN binding sites, the m and the d receptors, strategically located at substrates or inhibitors is stabilized within the active site of the various levels of nociceptive pathways (2). This can be realized peptidase by interacting with a glutamate residue (13). Taking by inhibition of the membrane-bound zinc metallopeptidases these results into account, we have selected compounds con- involved in the rapid inactivation of the enkephalins. One of taining a phosphinic moiety as a zinc coordinating ligand and these enzymes is neutral endopeptidase-24.11 (NEP, neprily- a free N-terminal amino group for optimal APN binding. sin, EC 3.4.24.11) and other one is an exopeptidase, amino- Numerous specific or multiple-phosphinic inhibitors of zinc metallopeptidases, particularly matrixins, have been described peptidase N (APN, EC 3.4.11.2). Biological studies performed (14), but none of them contains a free amino group that was on rat brain and spinal cord slices (3, 4) have shown that assumed to be detrimental for endopeptidase recognition. In The publication costs of this article were defrayed in part by page charge Abbreviations: NEP, neutral endopeptidase; APN, aminopeptidase N; payment. This article must therefore be hereby marked ‘‘advertisement’’ in ICV, intracerebroventricularly; DGNPA, Dansyl-Gly-(pNO2)Phe- accordance with 18 U.S.C. §1734 solely to indicate this fact. bAla. © 1998 by The National Academy of Sciences 0027-8424y98y9512028-6$2.00y0 *To whom correspondence should be addressed. e-mail: Roques@ PNAS is available online at www.pnas.org. pharmacie.univ-paris5.fr. 12028 Downloaded by guest on October 1, 2021 Pharmacology: Chen et al. Proc. Natl. Acad. Sci. USA 95 (1998) 12029 FIG. 1. Structure of the three families of dual NEPyAPN inhibi- tors. this study, we show that aminophosphinic-containing com- O O pounds of the general formula NH2 CH(R1)P(O) O O (OH)CH2 CH(R2)CONH CH(R3)COOH, in which the side chains have been selected for optimal recognition of NEP and APN, are the first dual competitive inhibitors with nano- molar affinities for both enzymes. As expected, these com- pounds were more potent than described dual APNyNEP inhibitors in both severe and chronic animal models of pain, thus providing a basis for the development of new analgesics fulfilling the gap between antalgics and opioids. MATERIALS AND METHODS Chemicals. Cbz-Phe-His-Leu (Cbz, carbobenzoxy) was from Bachem. Alanine p nitro-anilide was from Sigma, and Dansyl- b Gly-(pNO2)Phe- Ala (DGNPA) was prepared as described FIG. 3. Dixon plot analysis of the inhibitory activity of compound 9B for NEP and APN. The experiments were performed at 25°C in 50 (15). Details on the synthesis of the various inhibitors, sum- z marized in Fig. 2, will be described elsewhere. mM Tris HCl buffer (pH 7.4). (a) The inhibitory potency of 9B for NEP was measured by using DGNPA as substrate at the concentra- Assay For in Vitro NEP and APN Inhibition. NEP was tions indicated (h,5mm; Œ,10mM; E,25mM; ■,50mM; ‚, 100 mM). purified to homogeneity from rabbit kidney (16). IC50 values (b) The inhibitory potency of 9B for APN was measured by using 5 m were determined with DGNPA (Km 37 M) as substrate Ala-PNA as substrate at the concentrations indicated (h,25mM; Œ, according to the procedure described (15). Aminopeptidase 50 mM; E, 100 mM; ■, 200 mM). Each point of the Dixon plots from hog kidney was purchased from Boehringer Mannheim, represents the mean of triplicate determinations. These experiments 6 6 and inhibitory potencies were determined by using L-alanine- were repeated five times, leading to a mean Ki value ( SEM) of 0.80 5 m 0.05 nM for NEP and 2.5 6 0.3 nM for APN. p-nitroanilide (Ala-pNA, Km 400 M) as substrate (17). Dixon plot analyses (Fig. 3 a and b) of the inhibition of both In Vivo Inhibition of NEP. The inhibition of cerebral NEP, enzymes by compound 9B showed that this compound is a induced by i.v. injection of 100 mgykg compound 9B in mice, competitive inhibitor. The IC values of all the inhibitors 50 was evaluated as described (9). Fifteen minutes after injection, tested were transformed into Ki values by the Cheng–Prussof 5 y 1 y mice were anesthetized with chloral hydrate and were fixed by relationship (Ki IC50 1 S Km) (18). transcardial perfusion of paraformaldehyde, followed by phos- phate buffer. Then, the brain was removed, was homogenized in cold, 50 mM TriszHCl buffer, and was incubated with bestatin and captopril and with or without thiorphan. Then, [3H]-D.Ala2-Leu-enkephalin was added, and the amount of [3H]Tyr-D.Ala-Gly was evaluated.
Recommended publications
  • Analytical Performance of an Immunoassay to Measure Proenkephalin ⁎ Leslie J
    Clinical Biochemistry xxx (xxxx) xxx–xxx Contents lists available at ScienceDirect Clinical Biochemistry journal homepage: www.elsevier.com/locate/clinbiochem Analytical performance of an immunoassay to measure proenkephalin ⁎ Leslie J. Donatoa, ,Jeffrey W. Meeusena, John C. Lieskea, Deborah Bergmannc, Andrea Sparwaßerc, Allan S. Jaffea,b a Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, United States b Division of Cardiology, Mayo Clinic, Rochester, MN 55905, United States c Sphingotec GmbH, Hennigsdorf, Germany ARTICLE INFO ABSTRACT Keywords: Background: Endogenous opioids, enkephalins, are known to increase with acute kidney injury. Since the mature Biomarkers pentapeptides are unstable, we evaluated the performance of an assay that measures proenkephalin 119–159 Proenkephalin (PENK), a stable peptide formed concomitantly with mature enkephalins. Enkephalin Methods: PENK assay performance was evaluated on two microtiterplate/chemiluminescence sandwich im- Pro-enkephalin munoassay formats that required 18 or 1 h incubation times. PENK concentration was measured in plasma from penKid healthy individuals to establish a reference interval and in patients with varied levels of kidney function and Assay validation comorbidities to assess the association with measured glomerular filtration rate (mGFR) using iothalamate clearance. Results: Assay performance characteristics in plasma were similar between the assay formats. Limit of quanti- tation was 26.0 pmol/L (CV = 20%) for the 1 h assay and 17.3 pmol/L (CV = 3%) for the 18 h assay. Measurable ranges were 26–1540 pmol/L (1 h assay) and 18–2300 pmol/L (18 h assay). PENK concentrations are stable in plasma stored ambient to 10 days, refrigerated to at least 15 days, and frozen to at least 90 days.
    [Show full text]
  • Behavioral and Brain Sciences Plasticity: Implications for Opioid
    Behavioral and Brain Sciences http://journals.cambridge.org/BBS Additional services for Behavioral and Brain Sciences: Email alerts: Click here Subscriptions: Click here Commercial reprints: Click here Terms of use : Click here Plasticity: Implications for opioid and other pharmacological interventions in specific pain states Anthony H. Dickenson Behavioral and Brain Sciences / Volume 20 / Issue 03 / September 1997, pp 392 ­ 403 DOI: null, Published online: 08 September 2000 Link to this article: http://journals.cambridge.org/abstract_S0140525X97241488 How to cite this article: Anthony H. Dickenson (1997). Plasticity: Implications for opioid and other pharmacological interventions in specific pain states. Behavioral and Brain Sciences,20, pp 392­403 Request Permissions : Click here Downloaded from http://journals.cambridge.org/BBS, IP address: 144.82.107.43 on 10 Aug 2012 BEHAVIORAL AND BRAIN SCIENCES (1997) 20, 392±403 Printed in the United States of America Plasticity: Implications for opioid and other pharmacological interventions in specific pain states Anthony H. Dickenson Department of Pharmacology, University College London, London WC1E 6BT, United Kingdom Electronic mail: anthony.dickenson6ucl.ac.uk Abstract: The spinal mechanisms of action of opioids under normal conditions are reasonably well understood. The spinal effects of opioids can be enhanced or reduced depending on pathology and activity in other segmental and nonsegmental pathways. This plasticity will be considered in relation to the control of different pain states using opioids. The complex and contradictory findings on the supraspinal actions of opioids are explicable in terms of heterogeneous descending pathways to different spinal targets using multiple transmitters and receptors ± therefore opioids can both increase and decrease activity in descending pathways.
    [Show full text]
  • Antitumor Activity of Actinonin in Vitro and in Vivo
    Vol. 4, 171-176, January 1998 Clinical Cancer Research 171 Antitumor Activity of Actinonin in Vitro and in Vivo Yang Xu, Lawrence T. Lai, Janice L. Gabrilove, 8), mye!oid and monocytic cells, and most myeloblastic leuke- and David A. Scheinberg’ mias as well as on cells and tissues outside the hematopoietic system including fibroblasts, intestinal epithelium, renal tubular Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021 epithelium, and synaptic membranes of the central nervous system (I ). APN occurs as a homodimer, and the molecule is a 150-kDa, transmembrane glycoprotein with an intracellular ABSTRACT amino terminus (1). F23, an antihuman CD13/APN mAb, is able Actinonin, an antibiotic and CD13/aminopeptidase N to completely block the active site of the enzyme (9). (APN) inhibitor, has been shown to be cytotoxic to tumor Bestatin, a CD 1 3/APN inhibitor, was examined in preclin- cell lines in vitro. We investigated the antiproliferative ef- ical and clinical studies; bestatin could inhibit lymph node fects of actinonin on human and murine leukemia and lym- metastasis of P388 leukemia in mice (10) and was used in phoma cells. Actinonin inhibited growth of NB4 and HL6O clinical trials in malignant skin tumors (1 1), in head and neck human cell lines and AKR mouse leukemia cells in vitro with cancer (12), in esophageal cancer (13), and in gynecologic an IC50 of about 2-S g/ml. The inhibitory effect on CD13- tumors (14). High doses of bestatin resulted in the significant positive cells was not blocked by pretreatment with the inhibition of preexisting experimental and spontaneous metas- anti-CD13/APN monoclonal antibody F23, which binds with tasis in mice (15).
    [Show full text]
  • Cardioprotective Properties of Opioid Receptor Agonists in Rats with Stress-Induced
    Cardioprotective Properties of Opioid Receptor Agonists in Rats with Stress-Induced Cardiac Injury Ekaterina S. Prokudinaa B, Leonid N. Maslova* A, D, E, F, Natlia V. Naryzhnayaa B,G, Sergey Yu. Tsibulnikova B,C,E, Yury B. Lishmanova,b D, John E. Madias PhD c D,E, Peter R. Oeltgen PhD d D,E aLaboratory of Experimental Cardiology, Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences 634012 Tomsk, Russia. bLaboratory of Nuclear Medicine, National Research Tomsk Polytechnic University, Tomsk, Russia. cIcahn School of Medicine at Mount Sinai, and the Division of Cardiology, Elmhurst Hospital Center, New York, New York, USA. dDepartment of Pathology, University of Kentucky College of Medicine, Lexington, KY, USA * Correspondence: Leonid N. Maslov, MD, PhD, DSci, Professor of Pathological Physiology Laboratory of Experimental Cardiology, Federal State Budgetary Scientific Institution «Research Institute for Cardiology», Kyevskaya 111A, 634012 Tomsk, Russia Tel. +7 3822 262174 E-mail address: [email protected] Short title: Stress cardiomyopathy and opioid receptors Summary Purpose The objectives of this study were to investigate the role of endogenous opioids in the mediation of stress-induced cardiomyopathy (SIC), and to evaluate which opioid receptors regulate heart resistance to immobilization stress. Methods Wistar rats were subjected to 24 h 1 immobilization stress. Stress-induced heart injury was assessed by 99mTc-pyrophosphate accumulation in the heart. The opioid receptor (OR) antagonists (naltrexone, NxMB - naltrexone methyl bromide, MR 2266, ICI 174.864) and agonists (DALDA, DAMGO, DSLET, U-50,488) were administered intraperitoneally prior to immobilization and 12 h after the start of stress. In addition, the selective µ OR agonists PL017 and DAMGO were administered intracerebroventricularly prior to stress.
    [Show full text]
  • Morphine Indiscriminatingly Overstimulates All Opioid Receptors Including Those Not Involved in (Morphine) Pain Control (Exogenous)
    Extensions des propriétés des inhibiteurs mixtes des enképhalinases aux douleurs de la sphère cranio-faciale. Nouvelles applications à la migraine et aux douleurs de la cornée. Bernard P. Roques Professeur Emérite, Université Paris Descartes Unité 1267 Inserm, 4 avenue de l’Observatoire, 75006 Paris. ATHS Biarritz, 1-4 Octobre 2019 CONFIDENTIAL 1 Endorphins and their receptors. Endomorphin-1 Tyr – Pro – Trp – Phe – NH2 Endomorphin-2 Tyr – Pro – Phe – Phe – NH2 2 2 Drug Discovery : designing the ideal opioid (From B.L. Kieffer, Nature (2016), 537, 170-171) 3 Three levels of pain control by endogenous opioid system (EOS) EOS EOS Attacking pain at EOS its source Relieving or reducing pain at its source More than 50% of MO effects are attributable to peripheral neurons (nociceptors) Roques, B.P., Fournié-Zaluski, M.C. and Wurm, M., Nature Reviews Drug Discovery, 2012 4 DENKIs: mechanism of action The endogenous opioid system (EOS) is present at all levels of physiological-nociceptive control i.e. periphery, spinal cord and brain Elements of the EOS are opioid receptors, enkephalins and their inactivating enzymes Dual Inhibitors of ENKephalinases (DENKIs) potentiate physiological functions of DENKI enkephalins (e.g. pain control) only on those pathways where they are tonically released Enkephalinases APN NEP No adverse effects Enkephalins Y G G F M(L) (endogenous) Opioid receptors Morphine indiscriminatingly overstimulates all opioid receptors including those not involved in (Morphine) pain control (exogenous) Adverse effects 5 Synergistic combinations of the dual enkephalinase inhibitor PL265 given orally with various analgesic compounds acting on different targets in a murine model of bone cancer-induced pain.
    [Show full text]
  • The Inhibition of Enkephalin Catabolism by Dual Enkephalinase Inhibitor: a Novel Possible Therapeutic Approach for Opioid Use Disorders
    Alvarez-Perez Beltran (Orcid ID: 0000-0001-8033-3136) Maldonado Rafael (Orcid ID: 0000-0002-4359-8773) THE INHIBITION OF ENKEPHALIN CATABOLISM BY DUAL ENKEPHALINASE INHIBITOR: A NOVEL POSSIBLE THERAPEUTIC APPROACH FOR OPIOID USE DISORDERS ALVAREZ-PEREZ Beltran1*, PORAS Hervé 2*, MALDONADO Rafael1 1 Laboratory of Neuropharmacology, Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona Biomedical Research Park, c/Dr Aiguader 88, 08003 Barcelona, Spain, 2 Pharmaleads, Paris BioPark, 11 Rue Watt, 75013 Paris, France *Both authors participated equally to the manuscript Correspondence: Rafael Maldonado, Laboratori de Neurofarmacologia, Universitat Pompeu Fabra, Parc de Recerca Biomèdica de Barcelona (PRBB), c/Dr. Aiguader, 88, 08003 Barcelona, Spain. E-mail: [email protected] ABSTRACT Despite the increasing impact of opioid use disorders on society, there is a disturbing lack of effective medications for their clinical management. An interesting innovative strategy to treat these disorders consists in the protection of endogenous opioid peptides to activate opioid receptors, avoiding the classical opioid-like side effects. Dual Enkephalinase Inhibitors (DENKIs) physiologically activate the endogenous opioid system by inhibiting the enzymes responsible for the breakdown of enkephalins, protecting endogenous enkephalins, increasing their half-lives and physiological actions. The activation of opioid receptors by the increased enkephalin levels, and their well-demonstrated safety, suggest that DENKIs could represent a novel analgesic therapy and a possible effective treatment for acute opioid withdrawal, as well as a promising alternative to opioid substitution therapy minimizing side effects. This new pharmacological class of compounds could bring effective and safe medications avoiding the This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record.
    [Show full text]
  • (D-Ala*)Deltorphin II: D,-Dependent Stereotypies and Stimulation of Dopamine Release in the Nucleus Accumbens
    The Journal of Neuroscience, June 1991, 17(6): 1565-l 576 (D-Ala*)Deltorphin II: D,-dependent Stereotypies and Stimulation of Dopamine Release in the Nucleus Accumbens R. Longoni,’ L. Spina,’ A. Mulas,’ E. Carboni,’ L. Garau,’ P. Melchiorri,2 and G. Di Chiaral ‘Institute of Experimental Pharmacology and Toxicology, University of Cagliari, 09100 Cagliari, Italy and 21nstitute of Medical Pharmacology, University of Rome “La Sapienza,” 00185 Rome, Italy In order to investigate the relative role of central 6- and has been implicated in the stimulant actions of systemic opiates. F-opioid receptors in behavior, the effects of (D- Morphine-like opiates stimulate DA release preferentially in the Ala*)cleltorphin II, a natural Gopioid peptide, and PL017, nucleus accumbens (Di Chiara and Imperato, 1988a) and elicit a beta-casomorphin derivative specific for mu receptors, hypermotility sensitive to blockade by the DA D, receptor an- were compared after local intracerebral and intraventricular tagonist SCH 23390 (Longoni et al., 1987a). Intra-accumbens administration. lntracerebral infusion of the two peptides was infusion of opioid peptides elicits motor stimulation, but this done bilaterally in the limbic nucleus accumbens and in the action seems independent from DA, being resistant to classic ventral and dorsal caudate putamen of freely moving rats DA-receptor antagonists (neuroleptics; Pert and Sivit, 1977; Ka- through chronic intracerebral cannulas. After intra-accum- livas et al., 1983). Moreover, the syndrome elicited by intra- bens infusion, the two peptides elicited marked but opposite accumbens opiates is biphasic, as motor stimulation is typically behavioral effects: while (o-Ala2)deltorphin II evoked dose- preceded by motor inhibition and catalepsy (Costa11et al., 1978).
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8.247,609 B2 Roques Et Al
    USOO82476.09B2 (12) United States Patent (10) Patent No.: US 8.247,609 B2 Roques et al. (45) Date of Patent: Aug. 21, 2012 (54) AMINOACID DERIVATIVES CONTAININGA FOREIGN PATENT DOCUMENTS DSULFANYL GROUPIN THE FORM OF EP O262O53 3, 1988 MIXED DISULEANYLAND AMINOPEPTIDASEN INHIBITORS (Continued) (75) Inventors: Bernard Roques, Paris (FR): Marie-Claude Fournie-Zalluski, Paris OTHER PUBLICATIONS (FR) Silverman (The Organic Chemistry of Drug Design and Drug Action, (73) Assignee: Pharamleads, Paris (FR) 1992, Academic Press Inc.).* (*) Notice: Subject to any disclaimer, the term of this (Continued) patent is extended or adjusted under 35 U.S.C. 154(b) by 868 days. (21) Appl. No.: 12/146,941 Primary Examiner — Susanna Moore Assistant Examiner — Jennifer C Sawyer (22) Filed: Jun. 26, 2008 (74) Attorney, Agent, or Firm — Harness, Dickey & Pierce, (65) Prior Publication Data P.L.C. US 2009/OO12153 A1 Jan. 8, 2009 Related U.S. Application Data (57) ABSTRACT (63) Continuation-in-part of application No. 12/084,091, The invention relates to novel compounds of formula (I): filed as application No. PCT/EP2006/067711 on Oct. HN CH(R)-CH S S CH-CH(R) CONH 24, 2006. Rs, wherein R is a hydrocarbon chain, phenyl or benzyl (30) Foreign Application Priority Data radical, methylene radical substituted by a 5 or 6 atom het erocycle; R is a phenyl or benzyl radical, a 5 or 6 atom Oct. 25, 2005 (FR) ...................................... O5 10862 aromatic heterocycle, methylene group Substituted by a 5 or 6 May 5, 2006 (FR) ...................................... O6 O4030 atom heterocycle; Rs is a CH(R)—COOR radical, wherein R is hydrogen, an OH or OR group, a saturated hydrocarbon (51) Int.
    [Show full text]
  • Rôles Des Récepteurs Nucléaires Nur77 Et Nor-1 Et Des
    Rôles des récepteurs nucléaires Nur77 et Nor-1 et des neuropeptides enképhaline et dynorphine dans les comportements médiés par la dopamine et induits par les psychostimulants Thèse Céline Hodler Programme de doctorat en Neurobiologie Philosophiae doctor (Ph.D.) Faculté de médecine Québec, Canada © Céline Hodler, 2012 RÉSUMÉ Cette thèse démontre que les récepteurs nucléaires Nur77 et Nor-1 ainsi que les neuropeptides dynorphine (DYN) et enképhaline (ENK) sont des facteurs déterminants de la régulation du système dopaminergique. Notre premier manuscrit démontre d’une part que Nur77 et Nor-1 sont très clairement impliqués dans la régulation de l’homéostasie du système dopaminergique et qu’ils y jouent des rôles distincts, voire opposés, dans les conditions basales et dans les réponses comportementales et biochimiques aux psychostimulants. La délétion génétique de Nur77 augmente la proportion des récepteurs D2 en haute affinité (D2high), supprime les stéréotypies et perturbe la persistance de la préférence de place induites par l’administration répétée de psychostimulants. À l’inverse, la délétion de Nor-1 diminue la proportion des récepteurs D2high, atténue les comportements moteurs en réponse à l’amphétamine et supprime la sensibilisation comportementale. La délétion de Nor-1 module également l’expression de la DYN et de l’ENK favorisant ainsi une diminution de la réponse comportementale alors que celle de Nur77 induit l’effet inverse. Ainsi, Nor-1 et Nur77 jouent des rôles opposés, la délétion de Nor-1 tempère les comportements moteurs, celle de Nur77 les exacerbe. Notre second manuscrit démontre d’autre part que la DYN et l’ENK sont toutes deux nécessaires et ont des rôles opposés dans la manifestation des comportements de base médiés par la dopamine.
    [Show full text]
  • Enkephalin After Peptidase Inhibition
    J Pharmacol Sci 106, 295 – 300 (2008)2 Journal of Pharmacological Sciences ©2008 The Japanese Pharmacological Society Full Paper Great Increase in Antinociceptive Potency of [Leu5]Enkephalin After Peptidase Inhibition Kazuhito Akahori1, Kenya Kosaka1, Xing Lu Jin1, Yoshiharu Arai1, Masanobu Yoshikawa1, Hiroyuki Kobayashi1, and Tetsuo Oka1,* 1Department of Clinical Pharmacology, School of Medicine, Tokai University, Isehara 259-1143, Japan Received August 9, 2007; Accepted December 19, 2007 Abstract. Previous in vitro studies have shown that the degradation of [Leu5]enkephalin during incubation with cerebral membrane preparations is almost completely prevented by a mixture of three peptidase inhibitors: amastatin, captopril, and phosphoramidon. The present in vivo study shows that the inhibitory effect of [Leu5]enkephalin administered intra-third-ventricularly on the tail-flick response was increased more than 500-fold by the intra-third-ventricular pretreatment with the three peptidase inhibitors. The antinociceptive effect produced by the [Leu5]enkephalin in rats pretreated with any combination of two peptidase inhibitors was significantly smaller than that in rats pretreated with the three peptidase inhibitors, indicating that any residual single peptidase could inactivate significant amounts of the [Leu5]enkephalin. The present data, together with those obtained from previous studies, clearly demonstrate that amastatin-, captopril-, and phosphoramidon-sensitive enzymes play important roles in the inactivation of short endogenous opioid
    [Show full text]
  • New Trends in the Development of Opioid Peptide Analogues As Advanced Remedies for Pain Relief
    Current Topics in Medicinal Chemistry 2004, 4, 19-38 19 New Trends in the Development of Opioid Peptide Analogues as Advanced Remedies for Pain Relief Luca Gentilucci* Dipartimento di Chimica “G. Ciamician”, via Selmi 2, Università degli Studi di Bologna, 40126- Bologna, Italy Abstract: The search for new peptides to be used as analgesics in place of morphine has been mainly directed to develop peptide analogues or peptidomimetics having higher biological stability and receptor selectivity. Indeed, most of the alkaloid opioid counterindications are due to the scarce stability and the contemporary activation of different receptor types. However, the development of several extremely stable and selective peptide ligands for the different opioid receptors, and the recent discovery of the m-receptor selective endomorphins, rendered this search less fundamental. In recent years, other opioid peptide properties have been investigated in the search for new pharmacological tools. The utility of a drug depends on its ability to reach appropriate receptors at the target tissue and to remain metabolically stable in order to produce the desired effect. This review deals with the recent investigations on peptide bioavailability, in particular barrier penetration and resistance against enzymatic degradation; with the development of peptides having activity at different receptors; with chimeric peptides, with propeptides, and with non-conventional peptides, lacking basic pharmacophoric features. Key Words. Opioid peptide analogues; opioid receptors; pain; antinociception; peptide stability; bioavailability. INTRODUCTION. OPIOID PEPTIDES, RECEPTORS, receptor interaction by structure-function studies of AND PAIN recombinant receptors and chimera receptors [7,8]. Experiments performed on mutant mice gave new The endogenous opioid peptides have been studied information about the mode of action of opioids, receptor extensively since their discovery aiming to develop effective heterogeneity and interactions [9].
    [Show full text]
  • Replacement of Current Opioid Drugs Focusing on MOR-Related Strategies
    JPT-107519; No of Pages 17 Pharmacology & Therapeutics xxx (2020) xxx Contents lists available at ScienceDirect Pharmacology & Therapeutics journal homepage: www.elsevier.com/locate/pharmthera Replacement of current opioid drugs focusing on MOR-related strategies Jérôme Busserolles a,b, Stéphane Lolignier a,b, Nicolas Kerckhove a,b,c, Célian Bertin a,b,c, Nicolas Authier a,b,c, Alain Eschalier a,b,⁎ a Université Clermont Auvergne, INSERM, CHU, NEURO-DOL Pharmacologie Fondamentale et Clinique de la douleur, F-63000 Clermont-Ferrand, France b Institut ANALGESIA, Faculté de Médecine, F-63000 Clermont-Ferrand, France c Observatoire Français des Médicaments Antalgiques (OFMA), French monitoring centre for analgesic drugs, CHU, F-63000 Clermont-Ferrand, France article info abstract Available online xxxx The scarcity and limited risk/benefit ratio of painkillers available on the market, in addition to the opioid crisis, warrant reflection on new innovation strategies. The pharmacopoeia of analgesics is based on products that are often old and derived from clinical empiricism, with limited efficacy or spectrum of action, or resulting in Keywords: an unsatisfactory tolerability profile. Although they are reference analgesics for nociceptive pain, opioids are sub- Analgesia ject to the same criticism. The use of opium as an analgesic is historical. Morphine was synthesized at the begin- Mu opioid receptors (MORs) ning of the 19th century. The efficacy of opioids is limited in certain painful contexts and these drugs can induce Opioid adverse side effects potentially serious and fatal adverse effects. The current North American opioid crisis, with an ever-rising number Opioid abuse and misuse of deaths by opioid overdose, is a tragic illustration of this.
    [Show full text]